# A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (&gt;=10 to &lt;18 Years) With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03170518` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03170518](<https://clinicaltrials.gov/study/NCT03170518>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03170518

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.

## Technical summary

Registry record NCT03170518. Randomized; double masking; primary purpose treatment. Start 2017-07-21 (actual); primary completion 2023-09-20 (actual). Results posted on 2025-03-12.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 171 participants (enrolled count; ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Started: 2017-07-21 (actual) (ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Primary completion: 2023-09-20 (actual) (ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Completion: 2023-09-20 (actual) (ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Results first posted: 2025-03-12 (ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Countries: United States; Brazil; China; Greece; India; Malaysia; Mexico; Philippines; Poland; Russia (ClinicalTrials.gov record NCT03170518, source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03170518-2025-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (&gt;=10 to &lt;18 Years) With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Canagliflozin 100 mg
- Intervention (Drug): Canagliflozin 300 mg
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial (`cardio:pubmed-40759025`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3770c3c4018cddf431cef200c542bf9c7f8b460ed5deddbf8abebcb66d9b59ed
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
